Local delivery of antineoplastic drugs

"Local delivery of antineoplastic drugs" does not refer to a specific molecule, protein, receptor, enzyme, transporter, or other canonical therapeutic target. Instead, it describes a broad therapeutic strategy in which anticancer (antineoplastic) agents are administered directly at or near tumor sites using specialized drug delivery systems—such as nanoparticles, liposomes, hydrogels, polymeric implants, microneedles—to maximize intratumoral concentration while minimizing systemic exposure and toxicity. This approach can bypass physiological barriers like the blood-brain barrier and allows higher effective doses with reduced side effects compared to traditional systemic chemotherapy. The choice of locally delivered agent depends on tumor type and location; common examples include doxorubicin and paclitaxel among others. While this method improves safety profiles by reducing off-target effects on healthy tissues, it does not represent an individual biological entity but rather an evolving field within oncology therapeutics.

Other names

Local delivery of antineoplastic agentsLocal drug delivery for cancer therapy

Not applicable as this entry refers to a drug delivery strategy, not a molecular target. Mechanisms depend on the specific drug being delivered.